Therapy (HBV, HCV)

Ribozyme Product Results Presented

Published in Hepatitis Weekly, November 13th, 2000

In panel discussions, plenary sessions, and poster presentations at the Annual American Association for the Study of Liver Diseases (AASLD) Meeting, held in Dallas, Texas, during October 2000, Dr. Lawrence M. Blatt, Ribozyme Pharmaceuticals, Inc. (RPI) (RZYM), and other scientists presented information from collaborative studies of the company's anti-hepatitis C ribozyme, Heptazyme.

RPI also presented results of pre-clinical studies of RPI's anti-hepatitis B ribozyme product candidates having demonstrated marked efficacy in animal models.

Results were reported from a single dose volunteer study as well as from multidose studies of Heptazyme...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry